PATENT CLAIM ANALYSIS

Application Number: 16004039
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "183000"]

Abstract:
Embodiments of the present invention are directed to methods and dosage forms for treating inflammation and rejection in transplantation injuries with Bryostatin-1, Bryostatin-1 analogs and pharmaceutically acceptable salts thereof.

Claim (Index 32):
The dosage form of  claim 25  wherein said Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said oral dosage form in an amount of 0.001 to 0.1% by weight.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 94.0
- Lexical Diversity: 1.10714
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14502311', '13707264', '14954789', '14295875', '15474059']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7078326265020362
- 35 USC 102 Novelty (BERT): 0.6098331779136433
- Combined Prediction Score: 0.6980326816431969
- Mean Citation Score: 243.45456600000003
- Max Citation Score: 589.4071
- Similarity Product: 436.8689465592146

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test